&w=3840&q=100)
Insurance on WhatsApp: How to buy and manage policies, claim settlements
WhatsApp serves various daily purposes: messaging, booking travel tickets and making cashless payments. Now, insurance companies are using the digital platform for selling policies and settling claims.
Customers can manage their insurance plans in a WhatsApp conversation, just like texting a friend.
Several top insurers and platforms have rolled out WhatsApp-based services. Here's a look at the frontrunners:
HDFC ERGO General Insurance
WhatsApp number: +91 8169500500
Offers policy purchases, renewals, claims, and health card access, all within the chat. Real-time claim tracking and 24/7 support make the experience user-friendly.
ICICI Lombard General Insurance
WhatsApp Number: +91 7738282666
From cyber to health insurance, users can buy, renew, and even get health tips. Claim filing and document retrieval happen seamlessly through chat.
Policybazaar
WhatsApp Number: +91 8506013131
The insurance aggregator enables quick policy recommendations, document access, and two-wheeler insurance renewals via integrated payments.
Aditya Birla Health Insurance
WhatsApp Number: +91 8828800035
Aims for a hassle-free experience with options for premium payments, renewals, and document uploads — all within a guided chat interface.
Bajaj Allianz Life Insurance (BALIC)
WhatsApp Number: +91 8806727272
Offers over 20 services, including claim tracking and premium payment. Users can switch from chatbot to live support for complex queries.
Tata AIA Life Insurance
WhatsApp Number: +91 7045669966
Provides term plans, ULIPs, and wellness rewards in chat. Policy tracking and coverage customization are just a message away.
Why it matters
WhatsApp insurance offers:
Instant access to policy services
Less paperwork and app fatigue
Personalised support and reminders
Secure, in-chat payment options
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
11 minutes ago
- Hindustan Times
'Work weekends or stay late daily': Indian manager's shocking ultimatum to employees
A post about an Indian manager allegedly asking an employee to report to work on weekends for 8-hour shifts or add two days extra to their work hours for the coming week has sparked conversations around toxic workplaces among Reddit users. An individual posted a screenshot of a WhatsApp chat, claiming it's from the manager of one of their friends. An Indian manager's WhatsApp text on an office group has sparked anger among Reddit users. (Reddit/Awd_7, Unsplash (Representational image)/Muradi) 'This screenshot is from my friend's whatsapp group - the last msg is from her manager apparently having the audacity to normalise working on weekends,' the Reddit user wrote. In the screenshot, a part of a partially visible message reads, 'I have commitments and plans so unable to work on Saturdays and Sundays if possible I will try to complete.' It is followed by messages from other employees in the group chat who say they won't be able to work on Saturday and Sunday. In response, the manager slams one of the employees and says that the team's weekend unavailability will be addressed in the office the following week. 'This is not going to work, we need to plan something else, I will address the complete team on Monday, either we have to report to office on Saturday and Sundays for complete 8 hours or need to extend the shift on a daily basis for 2 hours for next three kindly prepare your mindset and come to work on Monday,' the message reads. The post on Reddit was published by an unverified user. has not independently verified the claims. An alleged text on WhatsApp from an Indian manager. (Reddit/@Awd_7) What did social media say? An individual suggested, 'They are literally stealing his labour. Refuse tactfully. If that doesn't work, refuse directly. Of course, he needs a new job soon.' Another added, 'They do it to reach you outside of work timings— they have no shame about it. Unless it's a genuine emergency, I simply ignore their calls/messages. I even had to block a colleague.' A third shared, 'Teams is documented. When they make requests like this, they don't want evidence. If someone goes to court, they can say it was a rogue manager. But on Teams, every message is logged; they can't do that.' A fourth wrote, 'Absolutely do not work a second on the weekend unless it's your own fault for not being able to in the week. Very slippery slope. Pretty sure none of us gets paid overtime for that.' Forced to work 20 unpaid hours: In a separate incident, a software developer claimed on Reddit about being pressured into working for 20 hours every week, on top of the standard working hours. The employee claimed that the overtime was unpaid. "That's 3 hours every weekday after work and my weekends completely gone,' the employee wrote on Reddit, adding, 'It's unpaid, non-negotiable, and they've made it clear that if I want to grow here, I have to do this.'
Hindustan Times
11 minutes ago
- Hindustan Times
FB friend from Japan dupes Powai businessman of ₹52 lakh in Bitcoin fraud
MUMBAI: A 65-year-old businessman from Powai lost ₹52 lakh after an allegedly Japanese woman he befriended online convinced him to invest in Bitcoins and duped him in a cybercrime fraud for a month. The West Cyber police had initially received his complaint, and as the defrauded amount was less than ₹1 crore, they forwarded it to the Andheri police station, which registered a case against the woman and her accomplices on Saturday. From the last week of June to July 17, the victim invested ₹ 52 lakh.(HT File Photo) According to the complaint, the businessman received a Facebook friend request from an unknown person in June. The profile had a woman's photo and displayed her employment with IBM in Hong Kong. Believing it to be genuine, the complainant accepted her request, and the two began communicating through the messenger app. Also Read | Senior citizen loses ₹21 lakh to gaming fraud During their conversation, the accused asked for his mobile number, and the two began to speak with each other on the phone. Her soft-spoken manner on calls gained the complainant's trust, he said in the complaint. She told him she was currently working in an IBM office based in Hong Kong and that she would soon be joining the IBM Crypto trading platform in Japan as a manager. The complainant continued to talk with her for 10 more days about various subjects. She would tell him how investing in Bitcoin reaps huge profits and how it could benefit him. Though the complainant was initially reluctant, he was eventually convinced. Also Read | Businessman duped of ₹8.75 crore in a forex trading fraud Once the complainant expressed interest, she sent him a link and asked him to create an ID for his virtual account. He said he began investing money in Bitcoins through the bank accounts she provided. From the last week of June to July 17, he had invested ₹52 lakh. When he checked the application, it displayed ₹10.3 crore as his virtual bank account balance. Noticing huge returns, the 65-year-old wanted to, but could not invest more money in Bitcoins. So, he decided to withdraw the balance accumulated in his account. When he inquired about the withdrawal process, he was asked to pay a 30% tax first. Finding this suspicious, he discussed it with his relatives and realised he had been defrauded. Also Read | Fraud impersonates bizman's US-based brother, swindles ₹50k The complainant first contacted the Cyber Helpline number 1930 and filed a complaint. The Andheri police on Saturday registered a case under sections 66 (d) (dishonestly receiving stolen computer resource or communication device) of the Information Technology Act, 2000, and sections 318 (4) (cheating), 319 (2) (cheating by personation), 336 (2) and 336 (3) (forgery), 338 (forgery of valuable security documents), 340 (2) (using forged electronic document as genuine) and 61 (2) (criminal conspiracy) of the Bhartiya Nyaya Sanhita, 2023. 'We are trying to ascertain the identities of and trace the accused through the transactions made by the complainant,' said a police officer from Andheri police station.
Economic Times
14 minutes ago
- Economic Times
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Hims & Hers Health (NYSE: HIMS) saw its stock plunge over 11% after the company reported its Q2 2025 earnings, marking its first-ever sequential revenue decline. While revenue jumped 73% year-over-year to $544.8 million, it still fell short of Wall Street's expectations of $552 million, and notably dropped from $586 million in Q1. The miss has rattled investor confidence, especially as GLP-1 weight-loss drug sales, a key growth driver, showed signs of slowing amid regulatory pressure and legal setbacks. Synopsis Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming weight-loss drug business. While year-over-year sales jumped 73%, revenue fell sequentially for the first time, causing investor worry. The company brought in $544.8 million, short of forecasts, with much of it tied to its GLP-1 obesity drug offerings. Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever sequential revenue decline, raising questions about the future of its GLP-1 obesity drug business. ADVERTISEMENT Despite its rapid annual growth, Hims & Hers posted Q2 revenue of $544.8 million, missing the analyst estimate of $552 million. The real concern? Revenue dropped from $586 million in Q1, marking the first quarter-over-quarter decline since the company went public. The stock currently trades at $63.35, regaining some ground after hitting an intraday low of $54.82. Despite opening at $64.00, it remains volatile, with an intraday high of $65.54. ALSO READ: Bullish IPO debut: Peter Thiel-backed crypto giant targets $4.2B valuation—is the new crypto wave knocking on Wall Street's door? The market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business segment. ALSO READ: Palantir stock soars after $1B Q2 earnings crush forecasts as AI demand fuels 110% YTD surge—now S&P 500's top performer ADVERTISEMENT With regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and Europe. Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Investors were caught off guard, as the slowdown came amid soaring demand for weight-loss drugs like semaglutide, a compound similar to the active ingredient in Wegovy and Ozempic. ADVERTISEMENT On the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings win. Investors appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent growth. ADVERTISEMENT Hims' biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged: Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA. ADVERTISEMENT A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic uncertainty. One bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental wellness. CEO Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product categories. If you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor: Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply uncertainty. For now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care ecosystem. What caused Hims & Hers stock to fall 11% after Q2 earnings? The company missed revenue estimates and saw its first-ever sequential drop in sales. Is the Hims weight-loss drug business facing trouble in 2025? Yes, due to FDA scrutiny and legal issues around compounded semaglutide. (You can now subscribe to our Economic Times WhatsApp channel) (Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.) Download The Economic Times News App to get Daily International News Updates. NEXT STORY
